Matches in SemOpenAlex for { <https://semopenalex.org/work/W2321855150> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- W2321855150 abstract "2083 Background: Neurofibromatosis 2 (NF2) is a tumor suppressor syndrome characterized by the presence of bilateral vestibular schwannomas (VS) and multiple meningiomas for which alternative treatments are desperately needed. Currently there are no well- tolerated agents that are clinically active. Previous groups have shown VEGF expression in small series of VS. In this study, we expand these findings and show a significant relationship between VEGF bound to the vascular endothelium and microvascular density (MVD) in NF2-related VS. This observation providing a strong rationale for the use of VEGF blockade in this patient population. Methods: Formalin-fixed, paraffin-embedded specimens were obtained from surgical resections of 22 patients with sporadic VS and from 21 patients with NF2 VS. Sections were stained with anti-VEGF polyclonal antibody and with anti-CD31 monoclonal antibody. Intensity of immunostaining of tumor cells for VEGF was scored in semi-quantitative fashion (0-none, +1-mild, +2-moderate, +3-strong); MVD was calculated by averaging the number of CD31-positive vessels in 5–15 high -powered fields (20x). MVD in tumors with and without VEGF bound to the vascular endothelium were compared using t-test. Results: Expression of VEGF was detected in all sporadic and NF2 VS. Strong expression of VEGF in tumor cells was more common in sporadic VS (45%) than in NF2-related VS (5%). In contrast, endothelial-bound VEGF was more common in NF2- related VS (75%) than in sporadic VS (45%). There was no difference in mean MVD between sporadic (6.2%) and NF2-related tumors (6.1%). However, in NF2-related VS, MVD was significantly greater in tumors with endothelial bound VEGF (7.4%) than without (4.6%) (p < 0.05). Conclusions: VEGF expression in tumor cells was universal in this series of sporadic and NF2-related VS. Although the intensity of VEGF expression appears greater in sporadic tumors, endothelial- bound VEGF is more common in NF2-related lesions and is associated with greater MVD. This finding indicates a potential activity of the VEGF angiogenic pathway in this patient population. Therefore anti-VEGF therapy, such as bevacizumab, sunitinib, or sorafinib, represents a rationale approach to treating NF2 patients with VS in which surgical approach is not possible or has failed. No significant financial relationships to disclose." @default.
- W2321855150 created "2016-06-24" @default.
- W2321855150 creator A5008943024 @default.
- W2321855150 creator A5012696704 @default.
- W2321855150 creator A5015585176 @default.
- W2321855150 creator A5059797681 @default.
- W2321855150 creator A5064586606 @default.
- W2321855150 creator A5091816977 @default.
- W2321855150 date "2007-06-20" @default.
- W2321855150 modified "2023-09-27" @default.
- W2321855150 title "Correlation between VEGF expression and MVD in sporadic and NF2-related schwannomas" @default.
- W2321855150 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.2083" @default.
- W2321855150 hasPublicationYear "2007" @default.
- W2321855150 type Work @default.
- W2321855150 sameAs 2321855150 @default.
- W2321855150 citedByCount "1" @default.
- W2321855150 crossrefType "journal-article" @default.
- W2321855150 hasAuthorship W2321855150A5008943024 @default.
- W2321855150 hasAuthorship W2321855150A5012696704 @default.
- W2321855150 hasAuthorship W2321855150A5015585176 @default.
- W2321855150 hasAuthorship W2321855150A5059797681 @default.
- W2321855150 hasAuthorship W2321855150A5064586606 @default.
- W2321855150 hasAuthorship W2321855150A5091816977 @default.
- W2321855150 hasConcept C117220453 @default.
- W2321855150 hasConcept C142724271 @default.
- W2321855150 hasConcept C143998085 @default.
- W2321855150 hasConcept C167734588 @default.
- W2321855150 hasConcept C2524010 @default.
- W2321855150 hasConcept C33923547 @default.
- W2321855150 hasConcept C502942594 @default.
- W2321855150 hasConcept C71924100 @default.
- W2321855150 hasConceptScore W2321855150C117220453 @default.
- W2321855150 hasConceptScore W2321855150C142724271 @default.
- W2321855150 hasConceptScore W2321855150C143998085 @default.
- W2321855150 hasConceptScore W2321855150C167734588 @default.
- W2321855150 hasConceptScore W2321855150C2524010 @default.
- W2321855150 hasConceptScore W2321855150C33923547 @default.
- W2321855150 hasConceptScore W2321855150C502942594 @default.
- W2321855150 hasConceptScore W2321855150C71924100 @default.
- W2321855150 hasLocation W23218551501 @default.
- W2321855150 hasOpenAccess W2321855150 @default.
- W2321855150 hasPrimaryLocation W23218551501 @default.
- W2321855150 hasRelatedWork W1804584583 @default.
- W2321855150 hasRelatedWork W1988183493 @default.
- W2321855150 hasRelatedWork W2002741407 @default.
- W2321855150 hasRelatedWork W2003820103 @default.
- W2321855150 hasRelatedWork W2018277294 @default.
- W2321855150 hasRelatedWork W2037831349 @default.
- W2321855150 hasRelatedWork W2056209969 @default.
- W2321855150 hasRelatedWork W2242689536 @default.
- W2321855150 hasRelatedWork W2321000773 @default.
- W2321855150 hasRelatedWork W2322331104 @default.
- W2321855150 isParatext "false" @default.
- W2321855150 isRetracted "false" @default.
- W2321855150 magId "2321855150" @default.
- W2321855150 workType "article" @default.